Spots Global Cancer Trial Database for Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
Official Title: A Phase 2 Study of Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer and Germline or Somatic DNA Repair Deficiency
Study ID: NCT02985021
Study Description
Brief Summary: In this study, patients who have metastatic prostate cancer that does not respond to hormone treatment and who have mutations in certain cancer-related genes will be treated with docetaxel and carboplatin chemotherapy.
Detailed Description: This is a phase 2 study of the combination of docetaxel and carboplatin in patients with germline inactivation of genes in the homologous recombination pathway, including BRCA1, BRCA2, and Ataxia Telangiectasia Mutated (ATM). PRIMARY OBJECTIVE To assess rate of 50% Prostate Specific Androgen (PSA) decline to docetaxel and carboplatin
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
VA Greater Los Angeles - West LA, Los Angeles, California, United States
VA Ann Arbor Health Care System, Ann Arbor, Michigan, United States
VA Puget Sound Health Care System, Seattle, Washington, United States
Contact Details
Name: Robert B Montgomery, MD
Affiliation: VA Puget Sound HCS
Role: PRINCIPAL_INVESTIGATOR
Name: Matthew Rettig, MD
Affiliation: VA Greater Los Angeles HCS
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
